Welcome to LookChem.com Sign In|Join Free

CAS

  • or

180847-24-9

Post Buying Request

180847-24-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

180847-24-9 Usage

General Description

t-Butyl 4-((3-bromophenoxy)methyl)piperidine-1-carboxylate is a chemical compound with the formula C19H27NO3Br. It is a piperidine derivative with a butyl ester group and a bromophenoxy substituent. t-Butyl 4-((3-bromophenoxy)methyl)piperidine-1-carboxylate is commonly used as a building block in organic synthesis and pharmaceutical research. It has potential applications in the development of new drugs and agrochemicals due to its unique structure and reactivity. t-Butyl 4-((3-bromophenoxy)methyl)piperidine-1-carboxylate is of interest to chemists and researchers for its diverse potential applications in various fields, and its synthesis and properties are the subject of ongoing studies.

Check Digit Verification of cas no

The CAS Registry Mumber 180847-24-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,0,8,4 and 7 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 180847-24:
(8*1)+(7*8)+(6*0)+(5*8)+(4*4)+(3*7)+(2*2)+(1*4)=149
149 % 10 = 9
So 180847-24-9 is a valid CAS Registry Number.

180847-24-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl 4-[(3-bromophenoxy)methyl]piperidine-1-carboxylate

1.2 Other means of identification

Product number -
Other names 4-(3-bromophenoxymethyl)piperidine-1-carboxylic acid tert-butyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:180847-24-9 SDS

180847-24-9Relevant articles and documents

Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine

Feng, Feng,Jiang, Xueyang,Li, Yuan,Lin, Tailiang,Liu, Chang,Liu, Wenyuan,Lyu, Weiping,Sun, Haopeng,Xie, Huanfang,Xu, Jian,Zou, Manxing

, (2021/07/02)

Acetylcholinesterase (AChE) inhibitors are currently the first-line drugs approved by the FDA for the treatment of Alzheimer's disease (AD). However, a short effective-window limits their therapeutic benefits. Clinical studies have confirmed that the combination of AChE inhibitors and neuroprotective agents exhibits better anti-AD effects. We have previously reported that the dual AChE/GSK3β (Glycogen synthase kinase 3β) modulators have both neuroprotective effects and cognitive impairment-improvement effects. In this study, we characterized a new backbone of the AChE/GSK3β inhibitor 11c. It was identified as a highly potent AChE inhibitor and was found superior to donepezil, the first-line drug for the treatment of AD. In vivo studies confirmed that 11c significantly inhibited the activity of AChE in the brain but had little effect on the activity of AChE in the intestine. This advantage of 11c was expected to reduce the peripheral side effects caused by donepezil. Furthermore, biomarker studies have shown that 11c also improved the levels of acetylcholine and synaptophysin in the brain and exhibited neuroprotective effects. Preliminary in vivo and in vitro research results underline the exciting potential of compound 11c in the treatment of AD.

TREATMENT OF OCULAR DISORDERS

-

Paragraph 0234, (2014/04/18)

The invention provides methods of treatment of ocular disorders, including ocular disease with an angiogenic component. In certain embodiments, the treatment comprises administration of a ROCK2 inhibitor and an angiogenesis inhibitor. In certain embodiments, the ROCK2 inhibitor is ROCK2 selective. In certain embodiments, the angiogenesis inhibitor is a VEGF antagonist, for example, and VEGFR2 antibody.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 180847-24-9